Prof. Peng Xie 谢鹏
Chief Physician, Professor
Radiation Oncology, Cancer Hospital of Shandong First Medical University (Shandong Cancer Hospital), Jinan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation and comprehensive treatment for gynecologic cancers, including cervical, endometrial, ovarian, uterine sarcoma, vaginal, vulvar, and gestational trophoblastic tumors. Specializes in recurrent, metastatic, or refractory cases, re-irradiation, proton therapy, MR-guided radiation, and pain-free brachytherapy.
Dr. Xie holds a PhD in Oncology and completed postdoctoral training at Memorial Sloan Kettering Cancer Center (2016–2017). With nearly 20 years of experience, Dr. Xie trained under experts including Yu Jinming, Nancy Lee, Kaled M. Alektiar, and Zhang Fuquan. Additional clinical training occurred in Copenhagen (2019), Peking Union Medical College Hospital, Sun Yat-sen University Cancer Center (2020–2022), and New York Proton Center (2024).
Professional roles
- Standing Committee Member, Multi-primary and Unknown Primary Tumor Professional Committee, China Anti-Cancer Association
- Standing Committee Member, Abdominal Tumor Comprehensive Treatment Branch, China Medical Education Association
- Chair, Gynecologic Oncology Branch, Shandong Young Medical Workers Association
- Chair, Tumor Brachytherapy Branch, Shandong Pain Medicine Association
Name order: in Chinese the family name comes first (Xie Peng). Papers usually list the name as Peng Xie or Xie P.
Selected publications
39 papers on PubMed matched by name and affiliation; 10 as first or senior author since 2016. Most recent first- or senior-author papers:
- Int J Cancer, 2026 (senior author): Coronavirus disease 2019 infection reduces EGFR-TKI efficacy in non-small cell lung carcinoma: Real-world evidence from a multicenter propensity-matched cohort. PubMed 41863042
- Int J Biol Macromol, 2026 (senior author): WITHDRAWN: USP18-FTO axis activates PI3K-AKT signaling to drive endometrial carcinoma progression. PubMed 42229644
- J Am Acad Child Adolesc Psychiatry, 2026 (senior author): Optimizing Pharmacological Treatment in Children and Adolescents With Major Depressive Disorder: An Individual Participant Data Analysis. PubMed 42167647
- Gynecol Oncol, 2026 (senior author): Radiation-induced acquired expression of PD-L1 and reprogramming of the tumor microenvironment in cervical cancer. PubMed 41500072
- Int Immunopharmacol, 2024 (senior author): Real-world outcomes of first-line maintenance therapy for recurrent or metastatic cervical cancer: A multi-center retrospective study. PubMed 38330795
- Front Immunol, 2023 (senior author): Editorial: The role of maintenance therapy (immunotherapy, targeted therapy, etc) in cancer control and biologic behavior of recurrent/metastatic cervical cancer. PubMed 37744378
- Ann Clin Lab Sci, 2021 (senior author): Predictive Value of let-7a for Cancer Cell Repopulation between Chemotherapy and Long-Term Survival: A Prospective Study. PubMed 34686505
- BMC Cancer, 2021 (senior author): A novel nomogram containing acute radiation esophagitis predicting radiation pneumonitis in thoracic cancer receiving radiotherapy. PubMed 34022830
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital. This name is shared by other researchers, so we checked that most papers list this doctor's hospital and department.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion